In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Strata Skin Sciences Inc (NASDAQ: SSKN), with a price target of $5. The company’s shares opened today at $3.
Pantginis said:
“Valuation and risks to price target achievement. We maintain our Buy rating with a price target of $5. Our price target is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, XTRAC, and project upside from: (1) increase in patients treated for lead indication psoriasis; and (2) increasing traction for XTRAC in its other approved indications, vitiligo and eczema/ atopic dermatitis.”
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -9.7% and a 35.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Strata Skin Sciences Inc with a $5 average price target.
See today’s analyst top recommended stocks >>
Based on Strata Skin Sciences Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $1.36 million. In comparison, last year the company had a GAAP net loss of $13.67 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
STRATA Skin Sciences, Inc. is a medical technology company, which engages in the design, development, and commercializing of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
